Cranbury Pharmaceuticals announces the FDA approval of its generic version of cabergoline, making the medication available for oral administration effective June 15, 2026. This regulatory clearance is poised to bolster the generic pharmaceutical market, likely driving increased competition against competing brand products to the benefit of payers and patients.